DFS Stock Recent News
DFS LATEST HEADLINES
U.S. credit card issuer Discover Financial posted a more than threefold increase in fourth-quarter profit on Wednesday, helped by a drop in provisions for credit losses and a rise in interest income.
RIVERWOODS, Ill.--(BUSINESS WIRE)--Discover Financial Services (NYSE: DFS) Fourth Quarter 2024 Results 2024 2023 YOY Change Total loans, end of period (in billions) $121.1 $128.4 (6%) Total revenue net of interest expense (in millions) $4,759 $4,180 14% Total net charge-off rate 4.64% 4.11% 53 bps Net income (in millions) $1,291 $366 253% Diluted EPS $5.11 $1.45 252% Discover Financial Services (NYSE: DFS) today reported net income of $1.3 billion or $5.11 per diluted share for the fourth qua.
Capital One Financial Corp COF reported better-than-expected earnings for the fourth quarter.
The 2024 Q4 earnings season has entered full swing, with this week's reporting docket stacked with many notable companies. Two financial giants, Discover Financial Services DFS and American Express AXP, are among the bunch.
This monthly article focuses on selecting high-growth dividend stocks with rapidly growing dividends rather than high current yields. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum, suitable for investors in the accumulation phase.
Rising interest and non-interest income might have favored DFS' fourth-quarter earnings, partially offset by higher operating expenses.
Beyond analysts' top -and-bottom-line estimates for Discover (DFS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Discover (DFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo
Discover (DFS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.